drugset / Trial / NCT03234738
A Phase 1 Safety and PK Study of IV TP-271
Phase 1
Completed
40 enrolled
Tetraphase Pharmaceuticals, Inc
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedSequentialQuadruple-blindOther
Summary
This is a single-center, randomized, placebo-controlled, double-blind, multiple-ascending-dose, inpatient study to assess the safety, tolerability, and pharmacokinetics of TP-271 in healthy subjects. Subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this study.
Timeline
- Start
- 2017-08-16
- Primary completion
- 2018-01-02
- Completion
- 2018-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TP-271 | Small molecule | 0.5 mg/kg | Intravenous |
| Comparator | TP-271 | Small molecule | 1 mg/kg | Intravenous |
| Comparator | TP-271 | Small molecule | 2 mg/kg | Intravenous |
| Comparator | TP-271 | Small molecule | 2.5 mg/kg | Intravenous |
| Comparator | TP-271 | Small molecule | 3 mg/kg | Intravenous |